Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Mar 10, 2024 3:28pm
226 Views
Post# 35925314

RE:RE:RE:RE:RE:RE:GCAR

RE:RE:RE:RE:RE:RE:GCAR

This information looks terrific.
The larger pharm general market is looking to expand via acquisitions. Onc has teamed up with GCAR, which is affwith previous PanCan.
so, both on a micro & macro level the outside looking in, is favourable for ONC.
All said, there needs to be & is expected to be a partnership this year.
A complete buy- out. Which IMHO, most would prefer, could happen anytime & without indications.
The mantra ":has not happened yet, therefore won't happen"  is outright silly.
Dofssco For example. Went through good years, bad years, great years.
They were aquired in an unsoliced takeover around its 75th year of being in business.
Point. For 75 years ++ anyone could have said. " has not been bought out in xxx years, therfore never will be"
That example applies to many if not all companies that have been bought out.
There was an obvious period of time when a takeover / buyout/ merger seemed not likely.
Then out of the  blue, the takeover happens.
Dofasco like many takeover firms, were bought when the assets & future income opportunities were worth more than existing trading range.
in that light? Is the potential of Pelareorep worth more than  existing  trading range? 
Absolutely!
With this massive in balance one of 3 things needs to happen.
The SP will recover to reflect the true value.
News will come out to validate the lack of interest.
The company will be taken out. 

with ALL of the recent study data showing only positive opportunities for Pela , that only leaves a price recovery or a takeover.

With Roche being deeply involved with the Goblet studies. Most recently announced expansion(s), Roche would seem to be the most likely candidate.
That said, Dofasco was involved with joint ventures,marketing collaborations & subsidiaries. None of which became the suitor.
The analysts have a consensus, there will be a partnership this year.
As I said before, they never predict buyouts. Just too many unknown variables.
The partnership is predictable because they must have some form of $$$ arrangement to proceed with phase 3.
Great week all.
 

 

<< Previous
Bullboard Posts
Next >>